Yayın:
Evaluation of potential drug-drug interactions in intensive care unit

dc.contributor.authorDağdelen, M. S.
dc.contributor.authorGülen, D.
dc.contributor.authorCeylan, I
dc.contributor.authorGirgin, N. K.
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentAnestezi ve Reanimasyon Ana Bilim Dalı
dc.contributor.orcid0000-0003-2613-0084
dc.contributor.orcid0000-0002-5882-1632
dc.contributor.researcheridABE-2447-2020
dc.date.accessioned2024-05-31T06:34:28Z
dc.date.available2024-05-31T06:34:28Z
dc.date.issued2021-01-01
dc.description.abstractOBJECTIVE: Potential drug-drug interactions (pDDIs) and adverse drug reactions (ADRs) may be frequently observed in critically ill patients because of multiple drug use. It is important to identify pDDIs before their progression to ADRs. This study aimed to determine the prevalence and effect of pDDIs and possible ADRs in intensive care patients.PATIENTS AND METHODS: In this retrospective cross-sectional study, the medical records of patients in the intensive care unit (ICU) of Bursa Uludag University Faculty of Medicine Hospital between January 1. 2018. and December 31. 2018. were examined. Medication orders were recorded on days 2, 5, and 10. pDDIs, defined using the lexi-interact (UpToDate, 2020), were classified based on the significance level.RESULTS: A total of 144 patients were included in this study, and from the 395 medication orders. 1,776 had pDDI. Of these interactions, 23.5% were major (n = 418), 71.4% were moderate (n = 1268), and 5.1% (n = 90) were minor. The majority of patients (96.9%) had at least one pDDI. There was a strong correlation between the number of drugs on days 2. 5, and 10 and the number of pDDIs (p < 0.001, p = 0.7; p < 0.001, p = 0.72; p < 0.001, p = 0.73, respectively). No significant correlation was found among the number of pDDIs. the APACHE II score, and the duration of ICU stay.CONCLUSIONS: The prevalence of pDDIs was high and there was a strong correlation between the number of drugs and pDDIs. Detection of potential interactions through clinical decision support systems and checker tools should be used to increase patient safety.
dc.identifier.doi10.26355/eurrev_202109_26798
dc.identifier.endpage5806
dc.identifier.issn1128-3602
dc.identifier.issue18
dc.identifier.scopus2-s2.0-85116145953
dc.identifier.startpage5801
dc.identifier.urihttps://doi.org/10.26355/eurrev_202109_26798
dc.identifier.urihttps://hdl.handle.net/11452/41599
dc.identifier.volume25
dc.identifier.wos000705057500024
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherVerduci Publisher
dc.relation.journalEuropean Review For Medical And Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPrevalence
dc.subjectPotential drug-drug interactions
dc.subjectAdverse drug reaction
dc.subjectIntensive care
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectPharmacology & pharmacy
dc.subjectPharmacology & pharmacy
dc.titleEvaluation of potential drug-drug interactions in intensive care unit
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Anestezi ve Reanimasyon Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Dağdelen_vd_2021.pdf
Boyut:
426.46 KB
Format:
Adobe Portable Document Format